The European Commission, EMA and the European medicines regulatory network have
developed a Q&A document to provide guidance to stakeholders on adaptations to the
regulatory framework to address challenges arising from the COVID-19 pandemic,
with a particular focus on crucial medicines for use in COVID-19 patients.